1. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients
    Gul Alco et al, 2015, Oncol Lett CrossRef
  2. Ki67 as a Biomarker of Prognosis and Prediction: Is it Ready for Use in Routine Pathology Practice?
    Constance Albarracin et al, 2014, Curr Breast Cancer Rep CrossRef
  3. Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer.
    Miroslava Juríková et al, 2016, Acta Histochem CrossRef
  4. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.
    Masaharu Seno et al, 2014, PLoS ONE CrossRef
  5. Association of clinical, histopathological and immunohistochemical prognostic factors of invasive breast tumors and thermographic findings
    Zvonimir Zore et al, 2015, Infrared Physics & Technology CrossRef
  6. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer
    Cynthia Brito Lins Pereira et al, 2017, Clinical Breast Cancer CrossRef
  7. Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients
    Li Ding et al, 2017, Bioengineered CrossRef
  8. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma
    Ozgul Ekmekcioglu et al, 2013, Nuclear Medicine Communications CrossRef
  9. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer.
    Ibrahim Tekedereli et al, 2013, Mol Ther Nucleic Acids CrossRef
  10. Clinical Significance of CK19 Negative Breast Cancer.
    Mamiko Fujisue et al, 2012, Cancers (Basel) CrossRef
  11. Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study
    Rumiko Tashima et al, 2015, PLoS ONE CrossRef
  12. Human Breast Cancer Tissues Contain Abundant Phosphatidylcholine(36∶1) with High Stearoyl-CoA Desaturase-1 Expression
    Yoshimi Ide et al, 2013, PLoS ONE CrossRef
  13. Breast Cancer Subtype and Distant Recurrence after Ipsilateral Breast Tumor Recurrence
    Makoto Ishitobi et al, 2013, Ann Surg Oncol CrossRef
  14. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients
    Fausto Petrelli et al, 2015, Breast Cancer Res Treat CrossRef
  15. null
    Jose Russo, 2016 CrossRef
  16. Correlating Tumor Stiffness with Immunohistochemical Subtypes of Breast Cancers: Prognostic Value of Comb-Push Ultrasound Shear Elastography for Differentiating Luminal Subtypes
    Max Denis et al, 2016, PLoS ONE CrossRef
  17. Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR
    Makoto Ishitobi et al, 2014, Breast Cancer CrossRef
  18. Pathological examination of breast cancer biomarkers: current status in Japan
    Shinobu Masuda, 2016, Breast Cancer CrossRef
  19. A Prognostic Model for Patients with Triple-Negative Breast Cancer: Importance of the Modified Nottingham Prognostic Index and Age
    Jeanny Kwon et al, 2017, J Breast Cancer CrossRef
  20. Survival time according to the year of recurrence and subtype in recurrent breast cancer
    Masahiro Nakano et al, 2015, The Breast CrossRef
  21. Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence
    Y. Okumura et al, 2015, European Journal of Surgical Oncology (EJSO) CrossRef
  22. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence
    Eman Abdelzaher et al, 2015, Tumor Biol. CrossRef
  23. Chromatin CKAP2, a New Proliferation Marker, as Independent Prognostic Indicator in Breast Cancer
    Han-Seong Kim et al, 2014, PLoS ONE CrossRef
  24. Unmanipulated native fat exposed to high-energy diet, but not autologous grafted fat by itself, may lead to overexpression of Ki67 and PAI-1
    Francisco Claro et al, 2015, SpringerPlus CrossRef
  25. Assessment of the Cancer Risk of the Fat-Grafted Breast in a Murine Model
    Francisco Claro et al, 2016, ASJOUR CrossRef
  26. Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer
    Mitsuhiro Hayashi et al, 2011, Int J Clin Oncol CrossRef
  27. Clinical implications of proliferation activity in T1 or T2 male gastric cancer patients
    Young-Woo Kim et al, 2015, Exp Mol Med CrossRef
  28. Role of Ki67 in predicting resistance to adjuvant tamoxifen in postmenopausal breast cancer patients.
    Heba M Elzawahry et al, 2013, J Egypt Natl Canc Inst CrossRef
  29. The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index
    Nobuyuki Arima et al, 2016, J Clin Pathol CrossRef
  30. Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab.
    Li Bian et al, 2014, Cancer Biol Ther CrossRef
  31. null
    Hadi Tadayyon et al, 2017 CrossRef
  32. FoxM1: Repurposing an oncogene as a biomarker
    Deeptashree Nandi et al, 2017, Seminars in Cancer Biology CrossRef
  33. Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis
    Alberto Gallardo et al, 2017, Breast Cancer Res Treat CrossRef
  34. Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information
    Zorka Inic et al, 2014, Clinical Medicine Insights: Oncology CrossRef
  35. Stromal expression of CD10 in invasive breast carcinoma and its correlation with clinicopathological parameters
    Azza M. Rizk et al, 2017, Egyptian Journal of Pathology CrossRef
  36. Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes
    Johannes Uhlig et al, 2017, Translational Oncology CrossRef
  37. Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study.
    G Martelli et al, 2017, Eur J Surg Oncol CrossRef
  38. Biological subtypes of breast cancer: Prognostic and therapeutic implications.
    Ozlem Yersal et al, 2014, World J Clin Oncol CrossRef
  39. Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer
    REIKI NISHIMURA et al, 2014 CrossRef
  40. MCM3: A Novel Proliferation Marker in Oral Squamous Cell Carcinoma.
    Ludmila de F Valverde et al, 2018, Appl Immunohistochem Mol Morphol CrossRef
  41. Automated digital image analysis and manual counting of Ki-67 proliferation index in patients with breast cancer
    Mervat M.F. El-Deftar et al, 2017, Egyptian Journal of Pathology CrossRef
  42. Evaluation of Involvement of Axillary Lymph Nodes with Ki-67 Expression in Patients with Breast Cancer
    Mahdi Asadi et al, 2018, Int J Cancer Manag CrossRef
  43. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score
    Parker C. Wilson et al, 2018, Breast J CrossRef
  44. Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting
    Ellen M. Langer et al, 2019, Cell Reports CrossRef
  45. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
    Reiki Nishimura et al, 2011, World J Surg Onc CrossRef
  46. Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients
    Manjiri M. Bakre et al, 2019, Cancer Med CrossRef
  47. Association between axillary lymph node status and Ki67 labeling index in triple-negative medullary breast carcinoma
    Z. Chu et al, 2015, Japanese Journal of Clinical Oncology CrossRef
  48. Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer
    Tímea Tőkés et al, 2019, Pathol. Oncol. Res. CrossRef
  49. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status
    Mehrdad Payandeh et al, 2016, Asian Pacific Journal of Cancer Prevention CrossRef
  50. Assessment of Ki-67 as a potential biomarker in patients with breast cancer
    Halla Mohamed Ragab et al, 2018, Journal of Genetic Engineering and Biotechnology CrossRef
  51. Prognostic Value of Ki-67 in Patients With Resected Triple-Negative Breast Cancer: A Meta-Analysis.
    Qiang Wu et al, 2019, Front Oncol CrossRef
  52. Prognostic value of the Ki-67 proliferation index in patients with triple negative breast carcinoma. Preliminary report
    Ángel Fernández et al, 2020, Invest Clin CrossRef
  53. Peritumor to tumor apparent diffusion coefficient ratio is associated with biologically more aggressive breast cancer features and correlates with the prognostication tools
    Hidemi Okuma et al, 2020, PLoS ONE CrossRef
  54. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients
    Monika Pizon et al, 2018, Int J Oncol CrossRef
  55. Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
    Nobuyuki Arima et al, 2018, Oncol Lett CrossRef
  56. Comparison of clinical outcomes between sentinel lymph node biopsy and axillary lymph node dissection in a single-center Z0011-eligible breast cancer cohort
    Heein Jo et al, 2020, Korean J Clin Oncol CrossRef
  57. Digital Image Analysis of Ki-67 Stained Tissue Microarrays and Recurrence in Tamoxifen-Treated Breast Cancer Patients


    Nina Gran Egeland et al, 2020, CLEP CrossRef
  58. HER2-positive pure mucinous breast carcinoma
    Xingjuan Zhao et al, 2020 CrossRef
  59. Cancer progression and the invisible phase of metastatic colonization.
    Christoph A Klein, 2020, Nat Rev Cancer CrossRef
  60. A comparative study between Ki67 positive versus Ki67 negative females with breast cancer: Cross sectional study
    Mowafak Masoud Bahaddin, 2020, Annals of Medicine and Surgery CrossRef
  61. Currently Applied Molecular Assays for Identifying ESR1 Mutations in Patients with Advanced Breast Cancer
    Nuri Lee et al, 2020, IJMS CrossRef
  62. Therapeutic Perspectives on the Modulation of G-Protein Coupled Estrogen Receptor, GPER, Function
    Milad Rouhimoghadam et al, 2020, Front. Endocrinol. CrossRef
  63. Postmenopausal Breast Cancer in Women, Clinical and Epidemiological Factors Related to the Molecular Subtype: A Retrospective Cohort Study in a Single Institution for 13 Years. Follow-Up Data
    Cristina Marinela Oprean et al, 2020, IJERPH CrossRef
  64. High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
    Simon J. Anderhub et al, 2019, Mol Cancer Ther CrossRef
  65. Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)
    Homa Seyedmirzaei et al, 2021, J Oncol Pharm Pract CrossRef
  66. Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience
    Mirco Pistelli et al, 2021, Journal of Oncology CrossRef
  67. Correlation between semiquantitative and volumetric 18F-FDG PET/computed tomography parameters and Ki-67 expression in breast cancer
    Nsreen R. A. Mohamadien et al, 2021 CrossRef
  68. Correlation between ER, PR, HER-2, and Ki-67 with the risk of bone metastases detected by bone scintigraphy in breast cancer patients: A cross sectional study
    Hanif Afkari et al, 2021, Annals of Medicine and Surgery CrossRef
  69. Self-Assembling Polypeptide Hydrogels as a Platform to Recapitulate the Tumor Microenvironment
    Dariusz Lachowski et al, 2021, Cancers CrossRef
  70. null
    Jose Russo, 2021 CrossRef
  71. Tumor in 3D: In Vitro Complex Cellular Models to Improve Nanodrugs Cancer Therapy
    Soraia Fernandes et al, 2020, CMC CrossRef
  72. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review.
    Sergiusz Łukasiewicz et al, 2021, Cancers (Basel) CrossRef
  73. null
    Jose Russo, 2021 CrossRef
  74. Expression of Ki67 in Triple Negative Breast Carcinoma and Its Correlation with Clinicopathological Variables – A Study from a Tertiary Care Center in Thrissur, Kerala
    Reshma Gopalakrishnan et al, 2021, jebmh CrossRef
  75. Determination of the risk factors for breast cancer survival using the Bayesian method, Yazd, Iran
    Vida Pahlevani et al, 2021, Adv Biomed Res CrossRef
  76. Slow degrading Mg-based materials induce tumor cell dormancy on an osteosarcoma-fibroblast coculture model
    Philipp Globig et al, 2021, Bioactive Materials CrossRef
  77. A review of prognostic and predictive biomarkers in breast cancer
    Elaheh Tarighati et al, 2022, Clin Exp Med CrossRef
  78. Feasibility of Shear Wave Elastography Imaging for Evaluating the Biological Behavior of Breast Cancer
    Chaoxu Liu et al, 2022, Front. Oncol. CrossRef
  79. MOLECULAR SUBTYPES OF BREAST CANCER
    Michael Abiodun Adeyanju, 2022, ijsr CrossRef
  80. Outcomes of Breast-Conserving Surgery Plus Radiation vs Mastectomy for All Subtypes of Early-Stage Breast Cancer: Analysis of More Than 200,000 Women
    Quyen D Chu et al, 2022 CrossRef
  81. Preclinical Therapeutic Assessment of a New Chemotherapeutics [Dichloro(4,4’-Bis(2,2,3,3-Tetrafluoropropoxy) Methyl)-2,2’-Bipryridine) Platinum] in an Orthotopic Patient-Derived Xenograft Model of Triple-Negative Breast Cancers
    Tzu-Chun Kan et al, 2022, Pharmaceutics CrossRef
  82. Cell Proliferation Measured by Ki67 Staining and Correlation to Clinicopathological Parameters in Operable Breast Carcinomas from Vietnamese and Swedish Patients
    null Vu Hong Thang et al, 2015, J. Anal. Oncol. CrossRef
  83. Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
    Reiki Nishimura et al, 2013, Oncology CrossRef
  84. Association between epidemiological and clinico-pathological features of breast cancer with prognosis, family history, Ki-67 proliferation index and survival in Tunisian breast cancer patients
    Najah Mighri et al, 2022, PLoS ONE CrossRef
  85. Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
    Wei-Xiang Qi et al, 2022, Journal of Oncology CrossRef
  86. Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression
    Esraa Magdy Abdelraouf et al, 2022, Life Sciences CrossRef
  87. Breast MRI Segmentation and Ki-67 High- and Low-Expression Prediction Algorithm Based on Deep Learning
    Yuan-Zhe Li et al, 2022, Computational and Mathematical Methods in Medicine CrossRef
  88. Comparison of Clinical, Histopathological, and Survival Outcomes of Pure and Mixed Mucinous Breast Carcinoma
    Ahmet Cem Esmer et al, 2022, Indian J Surg CrossRef
  89. Sentinel Node Biopsy Alone or With Axillary Dissection in Breast Cancer Patients After Primary Chemotherapy: Long-Term Results of a Prospective Interventional Study
    Gabriele Martelli et al, 2022 CrossRef
  90. Satellite Noncoding RNAs (ncRNA) as Cancer Biomarkers? New Insights from FA-SAT ncRNA Molecular and Clinical Profiles in Feline Mammary Tumors
    Daniela Ferreira et al, 2022, OMICS: A Journal of Integrative Biology CrossRef
  91. null
    Dilawar Khan et al, 2022 CrossRef